|
Breast Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
In the present study, the mRNA level of ASPP2 was found to be suppressed in breast tumors compared with that in adjacent normal breast tissues, and the expression of ASPP2 was also decreased in a series of breast cancer cell lines compared with that in MCF‑10A normal breast cells.
|
29568874 |
2018 |
|
Breast Carcinoma
|
0.330 |
Biomarker
|
disease |
CTD_human |
Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma.
|
28650484 |
2017 |
|
Breast Carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
Our study showed that miR-548d-3p/TP53BP2 pathway is critically involved in the proliferation and apoptosis of breast cancer cells and may be new therapeutic target of breast cancer cells.
|
26663100 |
2016 |
|
Breast Carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
We have previously shown that ASPP1 and ASPP2 are specific activators of p53; one mechanism by which wild-type p53 is tolerated in human breast carcinomas is through loss of ASPP activity.
|
12524540 |
2003 |
|
Malignant neoplasm of breast
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
In the present study, the mRNA level of ASPP2 was found to be suppressed in breast tumors compared with that in adjacent normal breast tissues, and the expression of ASPP2 was also decreased in a series of breast cancer cell lines compared with that in MCF‑10A normal breast cells.
|
29568874 |
2018 |
|
Mammary Neoplasms
|
0.320 |
AlteredExpression
|
group |
BEFREE |
In the present study, the mRNA level of ASPP2 was found to be suppressed in breast tumors compared with that in adjacent normal breast tissues, and the expression of ASPP2 was also decreased in a series of breast cancer cell lines compared with that in MCF‑10A normal breast cells.
|
29568874 |
2018 |
|
Malignant neoplasm of breast
|
0.320 |
Biomarker
|
disease |
CTD_human |
Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma.
|
28650484 |
2017 |
|
Mammary Neoplasms
|
0.320 |
AlteredExpression
|
group |
BEFREE |
Additionally, we found that ΔN-ASPP2 expression is increased in human breast tumors as compared to adjacent normal breast tissue; in contrast, ASPP2 is suppressed in the majority of these breast tumors.
|
27939881 |
2017 |
|
Mammary Neoplasms
|
0.320 |
Biomarker
|
group |
CTD_human |
Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma.
|
28650484 |
2017 |
|
Malignant neoplasm of breast
|
0.320 |
Biomarker
|
disease |
BEFREE |
Our study showed that miR-548d-3p/TP53BP2 pathway is critically involved in the proliferation and apoptosis of breast cancer cells and may be new therapeutic target of breast cancer cells.
|
26663100 |
2016 |
|
Glaucoma, Primary Open Angle
|
0.310 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
This supports that the TP53BP2 variant may represent the cause of POAG in this family.
|
28150229 |
2018 |
|
Glaucoma, Primary Open Angle
|
0.310 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
This supports that the TP53BP2 variant may represent the cause of POAG in this family.
|
28150229 |
2018 |
|
Glaucoma, Primary Open Angle
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
This supports that the TP53BP2 variant may represent the cause of POAG in this family.
|
28150229 |
2018 |
|
Neoplasm Invasiveness
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma.
|
28650484 |
2017 |
|
Carcinoma, Lobular
|
0.300 |
Biomarker
|
disease |
CTD_human |
Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma.
|
28650484 |
2017 |
|
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma.
|
28650484 |
2017 |
|
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma.
|
28650484 |
2017 |
|
Other deletions of part of a chromosome
|
0.200 |
Biomarker
|
disease |
MGD |
ASPP2 deficiency causes features of 1q41q42 microdeletion syndrome.
|
27447114 |
2016 |
|
Holoprosencephaly 10
|
0.200 |
Biomarker
|
phenotype |
MGD |
ASPP2 deficiency causes features of 1q41q42 microdeletion syndrome.
|
27447114 |
2016 |
|
Other deletions of part of a chromosome
|
0.200 |
Biomarker
|
disease |
MGD |
ASPP2 binds Par-3 and controls the polarity and proliferation of neural progenitors during CNS development.
|
20619750 |
2010 |
|
Holoprosencephaly 10
|
0.200 |
Biomarker
|
phenotype |
MGD |
ASPP2 binds Par-3 and controls the polarity and proliferation of neural progenitors during CNS development.
|
20619750 |
2010 |
|
Other deletions of part of a chromosome
|
0.200 |
Biomarker
|
disease |
MGD |
ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growth.
|
16702401 |
2006 |
|
Holoprosencephaly 10
|
0.200 |
Biomarker
|
phenotype |
MGD |
ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growth.
|
16702401 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The changes in tumor volume, adverse reactions and survival of patients in the TP group and rAd-p53 + TP group, and the levels of p53, ASPP2, inhibitory member of the ASPP family (iASPP) and P-gp in postoperative tumor tissues in the 3 groups were evaluated.
|
31424649 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RASSF10 Is a TGFβ-Target That Regulates ASPP2 and E-Cadherin Expression and Acts as Tumor Suppressor That Is Epigenetically Downregulated in Advanced Cancer.
|
31817988 |
2019 |